Literature DB >> 33451111

Impact of CNS Diseases on Drug Delivery to Brain Extracellular and Intracellular Target Sites in Human: A "WHAT-IF" Simulation Study.

Mohammed A A Saleh1, Elizabeth C M de Lange1.   

Abstract

The blood-brain barrier (BBB) is equipped with unique physical and functional processes that control central nervous system (CNS) drug transport and the resulting concentration-time profiles (PK). In CNS diseases, the altered BBB and CNS pathophysiology may affect the CNS PK at the drug target sites in the brain extracellular fluid (brainECF) and intracellular fluid (brainICF) that may result in changes in CNS drug effects. Here, we used our human CNS physiologically-based PK model (LeiCNS-PK3.0) to investigate the impact of altered cerebral blood flow (CBF), tight junction paracellular pore radius (pararadius), brainECF volume, and pH of brainECF (pHECF) and of brainICF (pHICF) on brainECF and brainICF PK for 46 small drugs with distinct physicochemical properties. LeiCNS-PK3.0 simulations showed a drug-dependent effect of the pathophysiological changes on the rate and extent of BBB transport and on brainECF and brainICF PK. Altered pararadius, pHECF, and pHICF affected both the rate and extent of BBB drug transport, whereas changes in CBF and brainECF volume modestly affected the rate of BBB drug transport. While the focus is often on BBB paracellular and active transport processes, this study indicates that also changes in pH should be considered for their important implications on brainECF and brainICF target site PK.

Entities:  

Keywords:  CNS diseases; blood–brain barrier; brain pharmacokinetics; passive transport

Year:  2021        PMID: 33451111      PMCID: PMC7828633          DOI: 10.3390/pharmaceutics13010095

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  105 in total

1.  Unsolved problems in comparing brain sizes in Homo sapiens.

Authors:  M Peters; L Jäncke; J F Staiger; G Schlaug; Y Huang; H Steinmetz
Journal:  Brain Cogn       Date:  1998-07       Impact factor: 2.310

2.  P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling.

Authors:  E C M De Lange; D J Vd Berg; F Bellanti; R A Voskuyl; S Syvänen
Journal:  Eur J Pharm Sci       Date:  2018-08-23       Impact factor: 4.384

3.  Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.

Authors:  Steffen Baltes; Alexandra M Gastens; Maren Fedrowitz; Heidrun Potschka; Volkhard Kaever; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2006-10-10       Impact factor: 5.250

4.  Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis.

Authors:  R Bouw; P Ederoth; J Lundberg; U Ungerstedt; C H Nordström; M Hammarlund-Udenaes
Journal:  Acta Anaesthesiol Scand       Date:  2001-03       Impact factor: 2.105

Review 5.  Transport processes in the formation of the cerebrospinal fluid.

Authors:  E M Wright
Journal:  Rev Physiol Biochem Pharmacol       Date:  1978       Impact factor: 5.545

6.  Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels.

Authors:  Hajar Al Feteisi; Zubida M Al-Majdoub; Brahim Achour; Narciso Couto; Amin Rostami-Hodjegan; Jill Barber
Journal:  J Neurochem       Date:  2018-08-01       Impact factor: 5.372

7.  Normal neuroanatomical variation in the human brain: an MRI-volumetric study.

Authors:  John S Allen; Hanna Damasio; Thomas J Grabowski
Journal:  Am J Phys Anthropol       Date:  2002-08       Impact factor: 2.868

Review 8.  Species differences in drug transporters and implications for translating preclinical findings to humans.

Authors:  Xiaoyan Chu; Kelly Bleasby; Raymond Evers
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-12-21       Impact factor: 4.481

9.  Effects of traumatic brain injury on cerebral high-energy phosphates and pH: a 31P magnetic resonance spectroscopy study.

Authors:  R Vink; T K McIntosh; M W Weiner; A I Faden
Journal:  J Cereb Blood Flow Metab       Date:  1987-10       Impact factor: 6.200

Review 10.  Evaluation of the Production and Absorption of Cerebrospinal Fluid.

Authors:  Masakazu Miyajima; Hajime Arai
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-07-28       Impact factor: 1.742

View more
  5 in total

Review 1.  In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.

Authors:  Yukiko Murata; Sibylle Neuhoff; Amin Rostami-Hodjegan; Hiroyuki Takita; Zubida M Al-Majdoub; Kayode Ogungbenro
Journal:  AAPS J       Date:  2022-01-13       Impact factor: 4.009

2.  Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.

Authors:  Sho Sato; Kota Matsumiya; Kimio Tohyama; Yohei Kosugi
Journal:  AAPS J       Date:  2021-06-03       Impact factor: 4.009

3.  The Extension of the LeiCNS-PK3.0 Model in Combination with the "Handshake" Approach to Understand Brain Tumor Pathophysiology.

Authors:  Makoto Hirasawa; Mohammed A A Saleh; Elizabeth C M de Lange
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.580

Review 4.  Understanding Drug Delivery to the Brain Using Liposome-Based Strategies: Studies that Provide Mechanistic Insights Are Essential.

Authors:  Firda Juhairiyah; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2021-10-28       Impact factor: 4.009

Review 5.  Understanding the Blood-Brain Barrier and Beyond: Challenges and Opportunities for Novel CNS Therapeutics.

Authors:  Elizabeth C M de Lange; Margareta Hammarlund Udenaes
Journal:  Clin Pharmacol Ther       Date:  2022-02-27       Impact factor: 6.903

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.